Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5247714 | 1.00 | MAPK14 (0.48) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL5252087 | 0.90 | MAPK11 (0.61) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL5252090 | 0.90 | MAPK11 (0.61) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL5850103 | 0.83 | MAPK14 (0.64) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL5849928 | 0.80 | MAPK14 (0.61) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL5251156 | 0.79 | MAPK14 (0.70) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL5248650 | 0.79 | MAPK14 (0.70) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL5249909 | 0.77 | MAPK14 (0.43) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL5249915 | 0.77 | MAPK14 (0.43) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL5251252 | 0.75 | MAPK14 (0.48) | MAPK14MAPK11MAPK13MAPK12KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1361225-B1 | COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS | SANKYO CO (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-7091352-B2 | Compounds substituted with bicyclic amino groups | SANKYO COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20040147525-A1 | Compounds substituted with bicyclic amino groups | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1361225-A1 | COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS | Sankyo Company, Limited (JP) | 2003-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147525-A1 | Compounds substituted with bicyclic amino groups | IL2, IL1B, IL4I1 | MAPK14 1355/4885MAPK11 1447/4885MAPK13 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.